Profile of agomelatine and its potential in the treatment of generalized anxiety disorder

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 1149-1155

  Levitan, Michelle Nigri ^a   Papelbaum, Marcelo ^a,b   Nardi, Antonio Egidio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

Author keywords

Agomelatine; Generalized anxiety disorder; Pharmacological treatment

Indexed keywords

AGOMELATINE; AMIODARONE; CIPROFLOXACIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; ESCITALOPRAM; FLUVOXAMINE; MEXILETINE; NORADRENALIN; PLACEBO; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; ZILEUTON;

ANTIDEPRESSANT ACTIVITY; CIRCADIAN RHYTHM; COMORBIDITY; DEPRESSION; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; LIVER FAILURE; LONG TERM CARE; MULTICENTER STUDY (TOPIC); NONHUMAN; OFF LABEL DRUG USE; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; RESTLESSNESS; REVIEW; RISK FACTOR; SEMI STRUCTURED INTERVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; TRANQUILIZING ACTIVITY; WEIGHT GAIN;

EID: 84929147504     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S67470     Document Type: Review

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: Author; 2013.
2. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British association for psychopharmacology. J Psychopharmacol. 2014;28(5):403–439.
3. Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother. 2013;14(2):175–184.
4. Fischer AG, Jocham G, Ullsperger M. Dual serotonergic signals: a key to understanding paradoxical effects? Trends Cogn Sci. In press 2014.
5. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14(5):697–710.
6. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007;3(2):185–191.
7. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954–964.
8. San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008;23(6):396–402.
9. Papp M, Gruca P, Boyer PA, Mocaër E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 2003;28(4):694–703.
10. De Berardis D, Fornaro M, Serroni N, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci. 2015;16(1):1111–1130.
11. MacIsaac SE, Carvalho AF, Cha DS, Mansur RB, McIntyre RS, et al. The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin Pharmacother. 2014;15(2):259–274.
12. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628–642.
13. Levitan MN, Papelbaum M, Nardi AE. A review of preliminary observations on agomelatine in the treatment of anxiety disorders. Exp Clin Psychopharmacol. 2012;20(6):504–509.
14. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S, et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010;25(2):95–102.
15. De Berardis D, Di Iorio G, Acciavatti T, et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets. 2011;10(1):119–132.
16. Li X, Borjigin J, Snyder SH. Molecular rhythms in the pineal gland. Curr Opin Neurobiol. 1998;8(5):648–651.
17. Servier Laboratories Ltd. Valdoxan (Agomelatine) Summary of Product Characteristics, 2009. Available online: http://emc.medicines.org.uk/medicine/21830/SPC/Valdoxan/. Accessed 25, January, 2015.
18. Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group, Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo controlled trial. J Clin Psychiatry. 2009;70(8):1228–1237.
19. Green B. Focus on agomelatine. Curr Med Res Opin. 2011;27(4):745–749.
20. Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs. 2009;23(suppl 2):27–34.
21. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16(2):93–100.
22. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28(3):329–333.
23. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010;71(5):616–626.
24. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012;15(3):417–428.
25. Kennedy SH. Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs. 2009;23(suppl 2):41–47.
26. Stein DJ, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms within depression. Hum Psychopharmacol. 2013;28(2):151–159.
27. Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17(5):239–247.
28. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10(5):661–673.
29. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68(11):1723–1732.
30. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol. 2010;25(6):305–314.
31. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressantagomelatine on the circadian rest-activity cycle and depressive andanxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with Sertraline. J Clin Psychiatry. 2010;71(2):109–120.
32. Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39–67.
33. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):561–566.
34. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Long-term treatment with agomelatine: prevention of relapse in patients with generalized anxiety disorder over 6 months. J Clin Psychiatry. 2012;73(7):1002–1008.
35. Stein DJ, Ahokas A, Márquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry. 2014;75(4):362–368.
36. Hoertel N, Le Strat Y, Blanco C, Lavaud P, Dubertret C. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety. 2012;29(7):614–620.
37. Rucci P, Gherardi S, Tansella M, et al. Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord. 2003;76(1–3):171–181.
38. Ruscio AM, Chiu WT, Roy-Byrne P, et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the national comorbidity survey replication. J Anxiety Disord. 2007;21(5):662–676.